Exprivia SpA
MIL:XPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Exprivia SpA
MIL:XPR
|
IT |
|
P
|
Practical Solution PCL
SET:TPS
|
TH |
|
P
|
Philip Morris CR as
PSE:TABAK
|
CZ |
|
Accolade Inc
NASDAQ:ACCD
|
US |
|
C
|
Crown Holdings Inc
XBER:CWN
|
US |
|
Poly Property Group Co Ltd
HKEX:119
|
HK |
|
U
|
US BioTec Inc
OTC:USBC
|
US |
|
Scentre Group
ASX:SCG
|
AU |
|
A
|
AJ Plast PCL
SET:AJ
|
TH |
|
H
|
Hecto Financial Co Ltd
KOSDAQ:234340
|
KR |
|
C
|
CosNine Co Ltd
KOSDAQ:082660
|
KR |
|
Brinks Co
NYSE:BCO
|
US |
|
CCC Intelligent Solutions Holdings Inc
NASDAQ:CCC
|
US |
|
A
|
AECI Ltd
JSE:AFE
|
ZA |
|
Broadridge Financial Solutions Inc
NYSE:BR
|
US |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is XPR's stock price target?
Not Available
XPR does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Exprivia SpA?
Projected CAGR
0%
Over the last 14 years, the compound annual growth rate for Revenue has been 6%. The projected CAGR for the next 1 year is 0%.
What is the Operating Income forecast for Exprivia SpA?
Projected CAGR
4%
Over the last 14 years, the compound annual growth rate for Operating Income has been 4%. The projected CAGR for the next 1 year is 4%.